Information letter to healthcare professionals regarding the medicinal product: TRANEXAM. Intravenous forms of tranexamic acid (tranexamic acid): serious, including fatal, adverse reactions due to inadvertent intrathecal administration

20.07.2026 296 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу: ТРАНЕКСАМ. Внутрішньовенні форми транексамової кислоти (tranexamic acid): серйозні, у тому числі летальні, побічні реакції внаслідок ненавмисного інтратекального введенняPDF · 601 КБ

Завантажити

Information letter to healthcare professionals regarding the medicinal product: TRANEXAM. Intravenous forms of tranexamic acid (tranexamic acid): serious, including fatal, adverse reactions due to inadvertent intrathecal administration

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals regarding the medicinal product: TRANEXAM. Intravenous forms of tranexamic acid (tranexamic acid): serious, including fatal, adverse reactions due to inadvertent intrathecal administration

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration